Our portfolio reflects our belief in backing bold founders and advancing technologies critical to national security—with real traction and lasting impact.
Our portfolio reflects our belief in backing bold founders and advancing technologies critical to national security—with real traction and lasting impact.
Humanetics is a biopharmaceutical company developing BIO 300, a novel radiation modulator aimed at improving outcomes in solid tumor cancer treatments, preventing lung damage from inflammation, and offering biodefense protection.
The Leonid Capital Partners Investor Portal offers secure, real-time access to investment insights, portfolio performance, and key documents, ensuring transparency and ease of management.
